乐普生物(02157)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02157 乐普生物

未开盘 08-26 16:08:03

3.975

+0.110

+2.85%

最高4.160	最低3.910	成交量1,520万
今开3.920	昨收3.865	日振幅6.47%
总市值71.71亿	流通市值71.71亿	总股本18.04亿
成交额6,135万	换手率0.84%	流通股本18.04亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02157","market":"HK","secType":"STK","nameCN":"乐普生物","latestPrice":3.975,"timestamp":1787731683003,"preClose":3.865,"halted":0,"volume":15203000,"delay":0,"changeRate":0.028460543337645503,"floatShares":1804000000,"shares":1804000000,"eps":0.17362773924290764,"marketStatus":"未开盘","change":0.11,"latestTime":"08-26 16:08:03","open":3.92,"high":4.16,"low":3.91,"amount":61347325,"amplitude":0.064683,"askPrice":3.99,"askSize":1000,"bidPrice":3.975,"bidSize":77000,"shortable":3,"etf":0,"ttmEps":0.1598208140349777,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787794200000},"marketStatusCode":0,"adr":0,"listingDate":1645545600000,"exchange":"SEHK","adjPreClose":3.865,"openAndCloseTimeList":[[1787707800000,1787716800000],[1787720400000,1787731200000]],"volumeRatio":1.10465,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02157","defaultTab":"news","newsList":[{"id":"1162366260","title":"港股创新药概念股集体走强，中国生物制药涨超20%，石药集团涨超16%","url":"https://stock-news.laohu8.com/highlight/detail?id=1162366260","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162366260?lang=zh_cn&edition=full","pubTime":"2026-08-20 09:59","pubTimestamp":1787191169,"startTime":"0","endTime":"0","summary":"8月20日，港股创新药概念股集体走强，$中国生物制药(01177)$涨超20%，$石药集团(01093)$涨超16%，$晶泰控股(02228)$、$金斯瑞生物科技(01548)$涨超12%，$乐普生物(02157)$、$康方生物(09926)$涨超11%，$荣昌生物(09995)$、$复星医药(02196)$涨超7%。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","IE00BZ08YS42.EUR","LU0072913022.USD","LNGR","IE0008368742.USD","LU0314109678.HKD","BK1191","KCAI","LU0880133367.SGD","IBBQ","LU0326950275.SGD","LU1226287792.SGD","01093","BK1617","LU0634319403.HKD","LU0417516738.SGD","LU0315179316.USD","MEDX","HK0000320264.USD","LU1152091168.USD","IE00BPRC5H50.USD","HK0000306701.USD","IE0008369823.USD","LU1152091754.HKD","LU1226288253.USD","BK1583","09995","KURE","01548","IE00B5MMRT66.SGD","LU2778985437.USD","LU0561508036.HKD","LU0348825331.USD","LU0417516571.SGD","06978","HK0000165453.HKD","LU1226288170.HKD","SG9999004220.SGD","BK1521","IE00B031HY20.USD","159992","IE00BZ08YR35.GBP","LU2039709279.SGD","LU1813983027.USD","BK1574","LU1226287529.USD","LU2399975544.HKD","VXUS","BK1576","LU1807302812.USD","LU1328277881.USD","LU2328871848.SGD","01177","LU1960683339.HKD","LU1226287875.USD","LU0540923850.HKD","LU0417516902.SGD","02196","LU1720050803.USD","BK1161","LU1951186391.HKD","IE00BZ08YT58.USD","LU0348767384.USD","LU0067412154.USD","BK1593","IE00B543WZ88.USD","HK0000320223.HKD","LU1794554557.SGD","LU0348766576.USD","LU0348827113.USD","LU1969619763.USD","HK0000306685.HKD","LU1008478684.HKD","BK4588","LU0348735423.USD","LU0140636845.USD","LU2488822045.USD","BK1589","BK1141","02228","02157","LU0501845795.SGD","LU1961090484.USD","LU1993786604.SGD","BK4585","LU2476274720.SGD","09926","LU2476274308.USD","LU0348783233.USD","LU0348784397.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660247492","title":"乐普生物-B(2157.HK)中期业绩：营收5.22亿元同比增12%，中期继续盈利","url":"https://stock-news.laohu8.com/highlight/detail?id=2660247492","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660247492?lang=zh_cn&edition=full","pubTime":"2026-08-20 09:01","pubTimestamp":1787187707,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1161","02157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660457094","title":"乐普生物(02157.HK)发布中期业绩，股东应占利润2739.3万元，同比下降34.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660457094","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660457094?lang=zh_cn&edition=full","pubTime":"2026-08-19 16:43","pubTimestamp":1787129033,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109093580","title":"乐普生物（02157）2026年中期营收达5.22亿元  商业化销售翻倍助力扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=1109093580","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1109093580?lang=zh_cn&edition=full","pubTime":"2026-08-19 16:42","pubTimestamp":1787128965,"startTime":"0","endTime":"0","summary":"8月19日，乐普生物科技股份有限公司披露截至2026年6月30日止六个月未经审计中期业绩。期内公司实现营收5.22亿元，同比增长12.1%，并连续两个报告期保持盈利，录得净利润0.25亿元。许可以及后续里程碑收入1.49亿元，主要源于CMG901及MRG007项目；受基数影响，较上年同期3.09亿元有所下降。CMG901一线联合治疗首名患者入组已触发4500万美元里程碑付款。财务表现方面，报告期内毛利4.75亿元；期末现金及现金等价物为6.85亿元。董事会宣布不派发中期股息。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157871549","title":"乐普生物(02157)拟于2026年8月19日审议2026年中期业绩及派息事宜","url":"https://stock-news.laohu8.com/highlight/detail?id=1157871549","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157871549?lang=zh_cn&edition=full","pubTime":"2026-08-07 19:05","pubTimestamp":1786100738,"startTime":"0","endTime":"0","summary":"乐普生物科技股份有限公司（02157）8月7日公告称，公司董事会会议定于2026年8月19日（星期三）举行。\n会议议程包括：  \n1. 审议及批准公司及其附属公司截至2026年6月30日止六个月的未经审计中期业绩及其发布；  \n2. 研究并考虑是否建议派发2026年中期股息（如有）；  \n3. 处理其他相关事项。\n公告显示，截至本公告日期，公司董事会由七名董事组成，其中执行董事两名，非执行董事两名，独立非执行董事三名。\n本次董事会结果及相关财务数据将在会议审议通过后另行公告。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654071182","title":"港股异动 | 乐普生物(02157)涨近4% CMG901全球III期临床试验CLARITY-GASTRIC01取得积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2654071182","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654071182?lang=zh_cn&edition=full","pubTime":"2026-07-28 15:28","pubTimestamp":1785223688,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，乐普生物涨近4%，早盘曾涨逾12%。截至发稿，涨3.83%，报4.61港元，成交额9164.84万港元。消息面上，7月28日，乐普生物发布公告，有关集团与AstraZeneca AB就抗体偶联药物候选药物CMG901合作的最新情况。截至本公告日期，CLARITY-Gastric01全球III期临床试验公布的积极顶线结果显示，与研究者选择的治疗方案相比，sonesitatug vedotin在二线及后线(2L+) Claudin 18.2阳性晚期胃癌患者中展现出具有统计学显著性且极具临床意义的总生存期改善。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1473028.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","IBBJ","IBBQ","KCAI","VXUS","BK1161","III","PSYK","02157","BK4588","BK4134","BMED","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654127078","title":"乐普生物：CMG901全球III期临床试验CLARITY-GASTRIC01达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2654127078","media":"南方财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654127078?lang=zh_cn&edition=full","pubTime":"2026-07-28 12:32","pubTimestamp":1785213120,"startTime":"0","endTime":"0","summary":"【乐普生物：CMG901全球III期临床试验CLARITY-GASTRIC01达主要终点】乐普生物（02157.HK）发布自愿公告，公告基本信息：公司于2026年7月28日发布自愿性公告，披露其与阿斯利康合作开发的抗体偶联药物CMG901（sonesitatugvedotin，AZD0901）全球III期临床试验CLARITY-GASTRIC01取得积极顶线结果。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607283823312261.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607283823312261.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","02157","IBBQ","MDTX","PSYK","BMED","III","IBBJ","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654078997","title":"乐普生物(02157.HK)：CMG901(AZD0901)全球III期临床试验CLARITY-GASTRIC01取得积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2654078997","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654078997?lang=zh_cn&edition=full","pubTime":"2026-07-28 12:31","pubTimestamp":1785213110,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02157","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136134951","title":"乐普生物（02157）与阿斯利康合作开发的CMG901全球III期CLARITY-GASTRIC01试验获积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1136134951","media":"公告速递","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136134951?lang=zh_cn&edition=full","pubTime":"2026-07-28 12:30","pubTimestamp":1785213046,"startTime":"0","endTime":"0","summary":"2026年7月28日，乐普生物科技股份有限公司发布自愿性公告称，其与AstraZeneca AB合作开发的抗体偶联药物候选药物CMG901在全球III期临床试验CLARITY-GASTRIC01中取得积极顶线结果。试验显示，与研究者选择的治疗方案相比，CMG901在二线及后线（2L+）Claudin 18.2阳性晚期胃癌患者中，实现了具有统计学显著性且临床意义重大的总生存期改善。除CLARITY-GASTRIC01外，AstraZeneca正开展多项针对胃癌、胰腺癌及胆道癌等适应症的CMG901临床研究，包括III期CLARITY-Gastric 02、II期GEMINI-PeriOp GC及II期CLARITY-PanTumour01等。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193879471","title":"乐普生物（02157.HK）公告监事变动 任方源接替赵力萱","url":"https://stock-news.laohu8.com/highlight/detail?id=1193879471","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193879471?lang=zh_cn&edition=full","pubTime":"2026-07-15 16:56","pubTimestamp":1784105775,"startTime":"0","endTime":"0","summary":"2026年7月15日，乐普生物科技股份有限公司发布公告称，监事会于同日收到职工代表监事赵力萱女士的书面辞任函。赵女士因寻求其他事业发展，辞去职工代表监事职务，自2026年7月15日起生效。赵女士确认其在任期内与董事会及监事会并无意见分歧，亦无其他需提呈股东注意的事项。同日，乐普生物职工代表大会选举任方源女士为新任职工代表监事，任期自2026年7月15日起至本届监事会任期届满之日止。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651455191","title":"乐普生物(02157.HK)：任方源获选举为职工代表监事","url":"https://stock-news.laohu8.com/highlight/detail?id=2651455191","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651455191?lang=zh_cn&edition=full","pubTime":"2026-07-15 16:53","pubTimestamp":1784105605,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651455169","title":"乐普生物(02157)：任方源获选举为职工代表监事","url":"https://stock-news.laohu8.com/highlight/detail?id=2651455169","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651455169?lang=zh_cn&edition=full","pubTime":"2026-07-15 16:53","pubTimestamp":1784105605,"startTime":"0","endTime":"0","summary":"智通财经APP讯，乐普生物(02157)发布公告，于2026年7月15日，本公司监事会(监事会)收到本公司职工代表监事赵力萱女士(赵女士)的书面辞任函，赵女士因寻求其他事业发展辞任本公司职工代表监事。其辞任自2026年7月15日起生效。任方源女士(任女士)于本公司职工代表大会(职工代表大会)获选举为本公司职工代表监事，任期自2026年7月15日起至本届监事会任期届满之日止。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1467839.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02157","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651291435","title":"创新药概念全线扬升 科伦博泰生物(06990)涨逾11% 机构指创新药企迎业绩兑现窗口","url":"https://stock-news.laohu8.com/highlight/detail?id=2651291435","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651291435?lang=zh_cn&edition=full","pubTime":"2026-07-15 11:07","pubTimestamp":1784084836,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股创新药概念盘中全线扬升，截至发稿，欧康维视生物-B 涨13.35%，科伦博泰生物涨11.20%，康方生物涨8.82%，信达生物涨8.72%，三生制药涨8.11%，康诺亚-B涨7.62%，药明合联涨7.52%，荣昌生物涨7.09%，乐普生物涨6.87%，亚盛医药涨6.26%。该机构持续看好国内创新药出海β向上可持续性，提示投资者关注2027年起众多前期已达成BD的分子将在海外开启商业化新周期所带来的投资机会。","market":"nz","thumbnail":"https://static.szfiu.com/news/20200908/MDgxZGVmMDU5NGQxM2FkZGQzODVkYTY4OWM4NjkxNzk5NzY4NzQ2MDU0.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200908/MDgxZGVmMDU5NGQxM2FkZGQzODVkYTY4OWM4NjkxNzk5NzY4NzQ2MDU0.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985914","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0540923850.HKD","BK1587","LU0417516738.SGD","LU0348827113.USD","02268","LU0348784397.USD","IBBQ","06990","06855","LU1961090484.USD","01477","06978","KURE","LU0348767384.USD","LU0348825331.USD","LU0502904849.HKD","BK1141","LU2097828474.EUR","LU2399975544.HKD","MEDX","LU2097828805.USD","LU0417516902.SGD","BK1161","BK1589","01801","LU2476274308.USD","BK1574","LU2097828631.EUR","09926","IE00B543WZ88.USD","SG9999014674.SGD","01530","02162","BK1191","IE00BPRC5H50.USD","LU2097828714.EUR","LU0561508036.HKD","LU0455707207.USD","LU0417516571.SGD","LU2097828557.USD","LU2778985437.USD","BK1583","BK1593","LU2488822045.USD","159992","LU2328871848.SGD","LU1720050803.USD","09995","LU0634319403.HKD","02157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651433251","title":"港股异动 | 乐普生物(02157)再涨超7% MRG007有望成为潜在同类最佳(BIC)药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2651433251","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651433251?lang=zh_cn&edition=full","pubTime":"2026-07-15 10:22","pubTimestamp":1784082177,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，乐普生物再涨超7%，月内累计涨幅接近30%。消息面上，乐普生物旗下MRG007临床申请已于今年5月正式获得国家药品监督管理局药品审评中心受理。MRG007凭借差异化技术优势，有望成为潜在同类最佳药物，进一步夯实公司在消化道肿瘤ADC领域的领先地位，并为后续全球多中心临床开发及潜在更多BD合作奠定坚实基础。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1467659.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["KCAI","BK4588","BK4585","VXUS","BK1161","02157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192383407","title":"乐普生物2026年6月股份变动月报表：股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1192383407","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192383407?lang=zh_cn&edition=full","pubTime":"2026-07-06 18:32","pubTimestamp":1783333940,"startTime":"0","endTime":"0","summary":"乐普生物科技股份有限公司于2026年7月6日披露2026年6月的证券变动月报表。报告显示，截至2026年6月30日，公司法定/注册股本总额为人民币18.04亿元，与上月底持平，期间并未进行新增发行、购回、注销或库藏股操作。在期权与激励计划、可换股票据以及其他可能导致股本变动的安排方面，月报披露并无相关事项。月报由乐普生物联席公司秘书李昀軼女士签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647082347","title":"港股异动 | 乐普生物(02157)午前涨超13% 机构指MRG006A有望推动肝癌精准治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2647082347","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647082347?lang=zh_cn&edition=full","pubTime":"2026-06-29 11:18","pubTimestamp":1782703131,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，乐普生物午前涨超13%，截至发稿，涨12.57%，报4.03港元，成交额3631.49万港元。消息面上，乐普生物在2026 ASCO上披露的MRG006A针对标准治疗失败后的晚期肝癌患者的I期临床试验数据相当优异。MRG006A切入的是全球尚无获批ADC的肝癌领域，代表的是尚未被充分开发的新路径，又已经初步跨过临床验证门槛。国联民生证券此前发布研报称，MRG006A是国内首个申报临床、全球首个进入临床阶段的GPC3靶向ADC，具备FIC潜质。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1460171.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK4588","02157","BK1161","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647475483","title":"创新药概念全线扬升 晶泰控股(02228)涨逾14% 机构指创新药仍为行业核心增量","url":"https://stock-news.laohu8.com/highlight/detail?id=2647475483","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647475483?lang=zh_cn&edition=full","pubTime":"2026-06-29 10:33","pubTimestamp":1782700428,"startTime":"0","endTime":"0","summary":"消息面上，华鑫证券新近研究表示，自2015年创新药审批改革开始，创新药逐步成为医药行业的核心增量。以恒瑞医药为代表的创新药企业，创新药的收入比重持续提升。6月份以来，已有药明康德等企业开始公告回购或增持方案，逐步扭转市场对医药行业的信心。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241108/NmNiNTg2NTUyNjE5NjAwNw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/NmNiNTg2NTUyNjE5NjAwNw==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1984679","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09995","02162","LU1328277881.USD","LU1961090484.USD","06855","BK1574","LU0348735423.USD","LU0348827113.USD","01093","LU1993786604.SGD","LU1008478684.HKD","IE00B543WZ88.USD","LU0417516571.SGD","LU0417516902.SGD","LU0540923850.HKD","LU1226287792.SGD","09969","LU0880133367.SGD","BK1583","LU0348766576.USD","02228","BK1141","LU1969619763.USD","159992","LU0072913022.USD","LU0326950275.SGD","LU1951186391.HKD","LU1226287529.USD","IE00BZ08YS42.EUR","09926","LU0634319403.HKD","LU1960683339.HKD","LU0315179316.USD","LU0067412154.USD","LU2476274308.USD","06978","LU0140636845.USD","LU0348825331.USD","LU0348784397.USD","LU2476274720.SGD","LU0348767384.USD","LU0348783233.USD","02157","LU1720050803.USD","02637","01530","HK0000165453.HKD","IE00B5MMRT66.SGD","LU1226288253.USD","IE00BZ08YR35.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642257725","title":"港股异动 | 乐普生物-B(02157)午后涨超6% MRG006A治疗晚期肝癌I期临床数据优异","url":"https://stock-news.laohu8.com/highlight/detail?id=2642257725","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2642257725?lang=zh_cn&edition=full","pubTime":"2026-06-12 14:55","pubTimestamp":1781247321,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，乐普生物-B午后涨超6%，截至发稿，涨4.74%，报3.98港元，成交额4149.5万港元。消息面上，乐普生物在2026 ASCO上披露的MRG006A针对标准治疗失败后的晚期肝癌患者的I期临床试验数据相当优异。MRG006A切入的是全球尚无获批ADC的肝癌领域，代表的是尚未被充分开发的新路径，又已经初步跨过临床验证门槛。值得注意的是，乐普生物此前宣布其自主研发的靶向 CDH17 的抗体偶联药物MRG007 的新药临床试验申请正式获得国家药品监督管理局药品审评中心受理。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453620.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK4588","02157","BK1161","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116936297","title":"乐普生物-B更新2026年5月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1116936297","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1116936297?lang=zh_cn&edition=full","pubTime":"2026-06-01 17:56","pubTimestamp":1780307796,"startTime":"0","endTime":"0","summary":"乐普生物科技股份有限公司于2026年6月1日发布截至2026年5月31日止的股份变动月报表，显示公司本月股本保持不变。根据公告，乐普生物-B的法定注册股本依旧为人民币1,804,439,838元，股票面值每股人民币1元。同时，公司确认，截至2026年5月31日，已符合香港联交所规定的最低公众持股量要求。本次公告由联席公司秘书李昀轶女士签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636853239","title":"乐普生物(02157)：范馨予获选举为监事会监事","url":"https://stock-news.laohu8.com/highlight/detail?id=2636853239","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2636853239?lang=zh_cn&edition=full","pubTime":"2026-05-19 19:38","pubTimestamp":1779190711,"startTime":"0","endTime":"0","summary":"智通财经APP讯，乐普生物(02157)发布公告，自2026年5月19日起，范馨予女士获选举为第二届监事会监事。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1443574.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02157"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.lepubiopharma.com","stockEarnings":[{"period":"1week","weight":-0.0884},{"period":"1month","weight":-0.1176},{"period":"3month","weight":-0.1074},{"period":"6month","weight":-0.1334},{"period":"1year","weight":-0.6036},{"period":"ytd","weight":-0.2223}],"compareEarnings":[{"period":"1week","weight":0.0062},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.0259},{"period":"6month","weight":-0.0367},{"period":"1year","weight":0.005},{"period":"ytd","weight":0.0009}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"乐普生物科技股份有限公司是一家主要从事医药产品销售及新药研发的公司。该公司聚焦于肿瘤治疗领域，尤其是靶向治疗及免疫治疗。该公司致力于通过抗体药物偶联物（ADC）技术开发平台开发创新型ADC。该公司的临床阶段候选药物涵盖靶向疗法药物和一种免疫治疗药物，具体包括MRG003、MRG002、CMG901、MRG004A、CG0070、MRG006A、MRG007、CTM012等。","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.070458},{"month":2,"riseRate":0.5,"avgChangeRate":0.087235},{"month":3,"riseRate":0.4,"avgChangeRate":-0.009016},{"month":4,"riseRate":0.8,"avgChangeRate":0.177486},{"month":5,"riseRate":0.4,"avgChangeRate":-0.041488},{"month":6,"riseRate":0.4,"avgChangeRate":-0.053819},{"month":7,"riseRate":0.6,"avgChangeRate":0.074049},{"month":8,"riseRate":0.4,"avgChangeRate":-0.021359},{"month":9,"riseRate":0.5,"avgChangeRate":0.085192},{"month":10,"riseRate":0.25,"avgChangeRate":-0.14162},{"month":11,"riseRate":0.25,"avgChangeRate":0.007333},{"month":12,"riseRate":0.25,"avgChangeRate":-0.05091}],"exchange":"SEHK","name":"乐普生物","nameEN":"LEPU BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"乐普生物(02157)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供乐普生物(02157)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"乐普生物,02157,乐普生物股票,乐普生物股票老虎,乐普生物股票老虎国际,乐普生物行情,乐普生物股票行情,乐普生物股价,乐普生物股市,乐普生物股票价格,乐普生物股票交易,乐普生物股票购买,乐普生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"乐普生物(02157)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供乐普生物(02157)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}